Quantum BioPharma Ltd. (NASDAQ: QNTM) closed a non-brokered private placement of 26 Class A multiple voting shares on Nov. 9, generating gross proceeds of C$80.86, and disclosed the results of its Nov. 10 annual general and special meeting, according to a company announcement. The dual disclosures matter because they concentrate voting power in insider hands while shareholders approved a slate of measures that could reshape the company’s capital structure and public identity.
The placement, priced at C$3.11 per share, was acquired equally by Xorax Family Trust, associated with CEO Zeeshan Saeed, and Fortius Research and Trading Corp., controlled by director Anthony Durkacz, with each taking 13 shares. Following the issuance, the aggregate voting power of Class A multiple voting shares rose from approximately 57.01% to 68.22%, a shift that gives insiders a firmer grip on corporate decisions even as the dollar amount raised—C$80.86—is negligible for working capital. The proceeds are designated for general working capital purposes under shareholder authorization granted in 2025.
At the meeting, shareholders elected all five director nominees, reappointed MNP LLP as auditor, and approved several resolutions, including authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power. They also backed a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1, and a potential corporate name change. The board retains discretion over whether and when to implement these measures, meaning the approvals are enabling rather than immediate.
The implications are twofold. The increase in insider voting control to nearly 70% reduces the influence of public shareholders over major decisions, a governance concern for investors in a company whose Class A multiple voting shares already commanded a majority. Separately, the authorization to issue more multiple voting shares to preserve that threshold, combined with a possible 10-for-1 consolidation, suggests management is preparing tools to manage the share price and listing requirements without ceding control. A name change could also signal a strategic repositioning.
Quantum BioPharma is a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse. Its lead candidate, Lucid-MS, is a patented new chemical entity shown preclinically to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The company also invented UNBUZZD and retains a 19.84% stake in Unbuzzd Wellness Inc., along with royalties of 7% of sales until payments reach $250 million, after which the rate drops to 3% in perpetuity.
For investors, the insider voting increase and the approved consolidation and name-change authorities are the key takeaways, as they could affect liquidity, index eligibility, and the balance of power between management and minority holders. The full press release is available at https://ibn.fm/UagXR, and ongoing updates are posted in the company’s newsroom at https://ibn.fm/QNTM. The announcement was distributed by BioMedWire, one of more than 75 brands in the Dynamic Brand Portfolio at IBN, which provides wire access through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution.
